Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.